Heidi A. Erlacher

Partner in Charge – Boston

Dr. Heidi Erlacher’s practice focuses on worldwide patent acquisition and strategic counseling for a wide range of clients, including startups, mid-size chemical and biotechnology companies and large pharmaceutical companies. Heidi’s practice spans the fields of chemistry and biochemistry, with particular emphasis on small molecule pharmaceuticals, nucleic acid therapeutics, drug conjugates, organic and organometallic chemistry and biochemistry.

Download full bio 


  • CinCor Pharma to Sell to AstraZeneca for Approximately $1.8 Billion 

  • Ovid - $75 Million IPO 

  • Cooley Advises on Nightstar + NuCana IPOs 

  • Zealand Pharma – $89 Million IPO 

  • Recro Pharma – $15 Million Follow-On  

  • View all


  • Suffolk University Law School
    JD, cum laude, 2003

  • Massachusetts Institute of Technology
    PhD, Organic Chemistry

  • Clark University
    BA, Chemistry
    summa cum laude with Highest Honors in Chemistry, 1989

Admissions & Credentials


U.S. Patent and Trademark Office


  • Boston Patent Law Association

  • American Intellectual Property Law Association

Rankings & Accolades

    IAM Patent 1000: Top Patent Lawyer

    LMG Life Sciences: “Patent Strategy Attorney of the Year” Finalist (2022)

    Super Lawyers: Intellectual Property